Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Hui K. Gan"'
Autor:
Andrea Mannucci, Adnan Nagrial, Catello Somma, Jason D. Lickliter, Jianjun Zou, Mark Voskoboynik, Michael Millward, Tarek Meniawy, Lianshan Zhang, Katherine Woods, Peter Grimison, Michael Lahn, Surein Arulananda, Hui K Gan, Pablo Fernandez-Penas, Andreas Behren, Bo Gao, Michelle Harrison, Howard Kallender, Stacey Luo
Publikováno v:
Drug Design, Development and Therapy. 14:1177-1189
Purpose Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian
Autor:
John Wu, Andrew G. Hill, Michael Millward, Catherine Barrow, Christopher Jackson, Michael P. Brown, William F. Patterson, Wendy Huang, Zhiyu Tang, Victoria Atkinson, Gary Richardson, Hui K Gan, Ben Tran, Yunxin Chen, Dewan Zeng, Lisa G. Horvath, Lusong Luo, Andrew Haydon, Michael B. Jameson, Lai Wang, Ben Markman, Jayesh Desai, Stephen Begbie, Phillip Parente, Adnan Nagrial, Benjamin Solomon, Michael Friedlander
Publikováno v:
Journal of Clinical Oncology
PURPOSE Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib
Autor:
B. Li, Michael Millward, Y. Xia, S. Frentzas, K.Y. Kwek, Jermaine Coward, Ben Tran, Hui K Gan, Jayesh Desai, M. Wang, Amy Prawira, X. Jin
Publikováno v:
Annals of Oncology. 31:S705-S706
Autor:
Adnan Nagrial, Xiaoping Jin, Anna Rachelle Mislang, Yu Xia, Jermaine Coward, Baiyong Li, Rasha Cosman, Hui K Gan, Kon Yew Kwek, Dennis Xia, Zhongmin Maxwell Wang
Publikováno v:
Journal of Clinical Oncology. 39:2630-2630
2630 Background: AK117 is a novel humanized IgG4 monoclonal antibody (mAb) targeting CD47, a macrophage immune checkpoint that allows tumor cells to evade immune destruction by phagocytic cells. CD47 is a target expressed in many cancers. However, th
Publikováno v:
Head & Neck. 39:1544-1549
Background Not-infrequently patients with head and neck cancer are also diagnosed with synchronous lung cancer or metachronous primary lung cancer, which complicates the treatment decisions and prognosis. Methods Patients were identified from a datab
Autor:
Christine Lebrun-Frenay, Giuseppe Lombardi, Craig Gedye, Andrew B. Lassman, Madan G. Kundu, Mark R. Gilbert, Andrés F. Cardona, Erik P. Sulman, Clemens Seidel, Peter Ansell, Marian S. Macsai, Matthias Preusser, Hui K Gan, Kenneth Aldape, Sigmund Hsu, Richard A. Peterson, Golnaz Moazami, Jeffrey S. Wefel, Suvajit Samanta, Michael A. Vogelbaum, Stephanie L. Pugh, Yaakov Stern, Antje Wick, Dmitry Bentsion, Minesh P. Mehta, Earle Bain, Filip de Vos, Terri S. Armstrong, Vincent Blot, Walter J. Curran, Tony J. C. Wang, Minhee Won
Publikováno v:
Neuro Oncol
RTOG 3508/AbbVie M13-813/INTELLANCE-1 was a phase 3 trial of depatuximab-mafodotin (depatux-m, formerly ABT-414) that accrued 639 patients with EGFR-amplified newly diagnosed GBM. At the pre-specified interim OS analysis, the futility criteria were m
Autor:
Louie Naumovski, JuDee Fischer, Peter Ansell, Christine M. Bestvina, Joseph Thaddeus Beck, Amber Wong, Benedito A. Carneiro, Janet Yikai Jin, Einat Shacham Shmueli, Hui K Gan, Randy Robinson, Kyriakos P. Papadopoulos
Publikováno v:
Journal of Clinical Oncology. 38:TPS3649-TPS3649
TPS3649 Background: ABBV-321 (serclutamab talirine) is an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate that consists of a humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD
Autor:
Anna K. Nowak, Seon Young Lee, Lawrence Cher, Weon Sup Lee, Adithya Balasubramanian, Hui K Gan, Anne Poh Long, Samantha Bowyer, Jin-San Yoo
Publikováno v:
Journal of Clinical Oncology. 38:e14545-e14545
e14545 Background: Recurrent GBM is difficult to treat. Single agent checkpoint blockade has not improved outcomes. Angiogenesis is a rational drug target for rGBM and targeting angiogenesis may benefit pseudoprogression and cerebral oedema. O is a f
Autor:
Sylvie Guichard, Sanjeev Forsyth, Danijela Levaci, Macarena I. de la Fuente, Mohammed M. Milhem, Patrick Kelly, Mark Rosenthal, Tobias Walbert, Yelena Mikhailov, Hui K Gan, Maria Vieito, Kate Lipford, Blythe Thomson, Brian A. Van Tine, Varun Monga, Howard Colman, Alexander Sedkov
Publikováno v:
Journal of Clinical Oncology. 38:2505-2505
2505 Background: Isocitrate dehydrogenase 1 mutations (mIDH1) are present in >70% of patients with Grade II/III gliomas resulting in production and accumulation of (R)-2-hydroxyglutarate causing DNA hypermethylation and promoting tumorigenesis. Oluta
Autor:
Fiona Scott, Sylvia J. Gong, Lawrence Cher, Paul Thomas, Hui K Gan, Jodie Palmer, Cameron Durrant, Sze Ting Lee, Andrew W. Boyd, Nancy Guo, Uwe Ackermann, Graeme O'Keefe, Kirsten Remen, Nicole Coombs, Eddie Lau, Kunthi Pathmaraj, Po Inglis, Andrew M. Scott, Bryan W. Day, Zarnie Lwin
Publikováno v:
Neuro Oncol
Glioblastoma (GBM) is the most frequent and lethal primary brain neoplasm. EphA3 is a tumor restricted antigen expressed in 38–40% of GBM and 100% of the tumor vasculature. Ifabotuzumab is a non-fucosylated IgG1κ antibody targeting EphA3 receptor.